Tempus CEO Eric Lefkofsky: A Blood Draw Can Catch Returning Cancer 6 to 12 Months Before a Scan

Tempus CEO Eric Lefkofsky reported a record quarter with 23% revenue growth, driven by 32% growth in cancer testing and 33% in data & AI applications. The company signed three $100M+ deals, including with Merck and Bristol Myers Squibb. Tempus claims its blood tests can detect cancer recurrence 6-12 months earlier than scans, leveraging its 600-petabyte data trove and 8,000 hospital integrations. The company is acquiring Personalis to expand into recurrence detection.

Original reporting
Published Nov 14, 2026, 4:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 15, 2026, 10:26 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
MARKET
Neutral
AI market analysis
Mentioned
$TEM
Relevance
7/10
AlphAI data visualization · based on finance.biggo.com
Decision brief

The 30-second read

Med
01

Why it matters

The combination of record revenue growth, multiple $100M+ contracts, and the Personalis acquisition positions Tempus for expanded MRD testing and data moat, likely supporting a bullish market reaction.

02

Market read

Tempus' strong quarter and acquisition could lift health‑tech and AI‑in‑healthcare equities, reinforcing sector momentum.

03

What to watch

Potential regulatory scrutiny of data privacy and competition from Natera could temper upside.

Relevance 7/10Novelty 7/10Timing: today

Background

Tempus AI, a Nasdaq‑listed precision oncology company, disclosed its September 2026 quarter results and strategic moves.

Market effects

Highlights accelerating AI adoption in oncology, may lift other health‑tech stocks.

U.S. biotech and health‑tech sector could see modest gains.

Shows growing importance of data‑driven cancer care worldwide.

Counterpoint

Acquisition integration risk could delay benefits, and high valuation may already price in growth.

Key entities

  • Tempus AI

    U.S. listed precision oncology data and testing firm.

  • Personalis

    MRD detection specialist being acquired by Tempus.

Related articles

$TEMMedAI 8/10

BTIG raises Tempus AI stock price target to $100 on data deals

BTIG raised its price target for Tempus AI (NASDAQ:TEM) to $100, citing strong quarterly results, raised guidance, and significant data deals, including a $200M agreement with Bristol Myers Squibb. The company reported 50% revenue growth and positive adjusted EBITDA. Other analysts also raised price targets, noting strong performance in data and diagnostics segments.

$TEMLow

Jefferies upgrades Tempus AI stock rating to hold, raises price target to $70

Jefferies upgraded Tempus AI (TEM) from Underperform to Hold, raising its price target to $70. The stock, currently at $78.48, has gained 43% in six months. The firm cited strong revenue growth, strategic collaborations, and FDA approval plans. Tempus reported Q3 2026 earnings of $0.07 per share, beating estimates, with revenue up 23% to $411.5 million. Needham raised its price target to $89, citing data business growth.

$TEMMed

Tempus AI Inc (TEM) Q3 2026 Earnings Call Highlights: Revenue Jumps 23%

Tempus AI Inc (TEM) reported Q3 2026 revenue of $411M, up 23%. CEO Lefkofsky expects sustainable 25%+ growth, with oncology and data segments driving performance. The company anticipates mid-2027 breakeven for Personalis' MRD test and predicts strong market share in MRD. Tempus also highlighted long-term data business commitments and AI-driven customer stickiness.